Abstract
Gastric cancer, or stomach cancer, is one of the most common and deadliest forms of cancer, killing approximately 770,000 people in the world annually. The efficacies of traditional cancer therapies, such as surgical treatment, radiation therapy and chemotherapy, are limited: however, chimeric antigen receptor (CAR) T-cell immunotherapy was recently developed as a groundbreaking approach to cancer treatment, genetically modifying a patient’s own T cells to express a CAR on the T cell surface in order to recognize specific tumor-associated antigens present on cancer cells. Significant efforts have been made to develop CAR T-cell therapies to treat solid tumors including gastric cancer in recent years. In this review, we summarize recent progress on CAR T-cell therapies for gastric cancer and focus on the most important targets for CAR T-cell immunotherapy in the context of gastric cancer. Finally, we discuss future directions of CAR T-cell therapies for gastric cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
